

ANNOUNCEMENT

CALL FOR ABSTRACTS

FINAL PROGRAM

## 3<sup>rd</sup> International CAA Conference

# CEREBRAL AMYLOID ANGIOPATHY AND RELATED MICROANGIOPATHIES

October 24-26, 2012

Leiden University Medical Center, Leiden, The Netherlands

The goal of the conference is to bring together leading international experts in  $\beta$ -amyloid metabolism, vascular biology, neuropathology, stroke genetics, brain imaging, and the clinical manifestations of cerebrovascular disease to present and discuss cutting-edge data in this rapidly developing field.

A special focus will be moving the field towards clinical trials of candidate disease-modifying treatments, in particular by establishing consensus on preclinical animal data and human biomarkers for CAA trials. Other topics of discussion will be early detection methods for presymptomatic CAA and the biological and clinical interactions between CAA and Alzheimer's disease.

The atmosphere for discussion is anticipated to be informal and lively, with ample opportunities for forming new collaborations and relationships within the growing CAA scientific and clinical communities.

Registration and information:  
[www.boerhaavenascholing.nl](http://www.boerhaavenascholing.nl)

# CEREBRAL AMYLOID ANGIOPATHY AND RELATED MICROANGIOPATHIES

## CONFERENCE DIRECTORS

**Mark A. van Buchem, MD, PhD**  
Professor and Chief of Neuroradiology  
Department of Radiology  
Leiden University Medical Center  
Leiden, The Netherlands

**Steven M. Greenberg, MD, PhD**  
Professor of Neurology  
Harvard Medical School  
Director, Hemorrhagic Stroke Research  
Massachusetts General Hospital  
Stroke Research Center  
Boston, Massachusetts, USA

## TARGET AUDIENCE

Neuroscience clinicians (neurologists, geriatricians, pathologists, radiologists, allied health professionals), and translational/basic researchers and biopharmaceutical investigators with an interest in amyloid, stroke, Alzheimer's disease, and brain aging.

## OBJECTIVES

At the completion of this program, participants should be better able:

- To discuss the pathogenesis of CAA and CAA-related brain injury in relation to cerebral amyloid deposition, based on information from human and animal model studies
- To consider biomarkers of  $\beta$ -amyloid deposition in cerebral blood vessels versus brain parenchyma, using novel neuroimaging techniques
- To discuss the relationship between familial and sporadic CAA and other hereditary conditions including familial Alzheimer disease
- To discuss the state of the art of emerging therapies for CAA
- To consider surrogate markers of disease that are instrumental in treatment trials in CAA

## ORGANIZING COMMITTEE

**Brian J. Bacsakai, PhD, Boston, USA**  
**Charlotte Cordonnier, MD, Lille, France**  
**Wiesje van der Flier, PhD, Amsterdam, the Netherlands**  
**Joost Haan, MD, PhD, Leiden, the Netherlands**  
**Mathias Jucker, PhD, Tübingen, Germany**  
**Jin-Moo Lee, MD, PhD, St. Louis, USA**  
**Joan Montaner, MD, PhD, Barcelona, Spain**  
**William van Nostrand, PhD, Stony Brook, New York, USA**  
**Eric Smith, MD, Calgary, Canada**  
**Harry V. Vinters, MD, Los Angeles, USA**

**Abstract submission** can be done to [boerhaavecongress-service@lumc.nl](mailto:boerhaavecongress-service@lumc.nl), deadline August 31 2012.  
Please add 'CAA' in the subject line.

**Venue:** Leiden University Medical Center, [www.lumc.nl](http://www.lumc.nl)

**Registration fees:** Physicians and faculty € 350,-. Allied Health Professionals and trainees € 200,-.  
Please note: fees increase after 31 August with € 100,-

**Accreditation** will be requested at the relevant professional societies.

**Practical information:** Boerhaave Congress Service, T: +31 71 526 8500, E: [boerhaavecongress-service@lumc.nl](mailto:boerhaavecongress-service@lumc.nl)

**Scientific information:** Elmi van Beelen, T: + 31 71 526 4376, E: [StafsecretariaatRadiologie@Lumc.nl](mailto:StafsecretariaatRadiologie@Lumc.nl)

*This will be the third international meeting to focus on cerebral amyloid angiopathy (CAA). The first was held in Reykjavik, Iceland in August 2007, the second in Los Angeles, California in May 2010, and the third will be organized in Leiden, the Netherlands. Leiden University Medical Center has a rich history in CAA research, having been the site where the first hereditary form of CAA associated with mutation of the  $\beta$ -amyloid precursor protein was identified and characterized.*

# CEREBRAL AMYLOID ANGIOPATHY AND RELATED MICROANGIOPATHIES

## FINAL PROGRAM

### Wednesday, October 24

8:30 – 9:30 Registration and coffee

Opening Session

9:30 – 9:35 Welcome *Mark van Buchem*

9:35 – 10:00 The story of HCHWA-D *Joost Haan*

#### Session 1. Detecting CAA: amyloid imaging and other biomarkers

Moderator: Harry Vinters

10:00 – 11:30 Plenaries

10:00 – 10:30 : Imaging (*Mark van Buchem*)

10:30 – 11:00 : Biomarkers in plasma and CSF (*Joan Montaner*)

11:00 – 11:30 : New agents for amyloid imaging (*Greg Zipfel*)

11:30 – 12:30 Submitted papers and/or short invited talks

12:30 – 14:00 Lunch

#### Session 2. CAA and Cerebrovascular Disease: markers and mechanisms

Moderator: Raj Kalaria

14:00 – 15:30 Plenaries

14:00 – 14:20 : Epidemiology (*Meike Vernooij*)

14:20 – 14:40 : Imaging (*David Werring*)

14:40 – 15:00 : Animal models I (*Brian Bacskai*)

15:00 – 15:20 : Animal models II (*Masafumi Ihara*)

15:30 – 16:00 Break

16:00 – 17:00 Submitted papers and/or short invited talks

### Thursday, October 25

#### Session 3. Hereditary CAA: lessons from DIAN and AD

Moderator: Wiesje van der Flier

8:30 – 10:00 Plenaries

8:30 – 9:00 : Lessons from the Dominantly Inherited Alzheimer Network (DIAN) (*Randall Bateman*)

9:00 – 9:30 : Lessons from Alzheimer's Disease (*Reisa Sperling*)

9:30 – 10:00 : Lessons from animal models (*Mathias Jucker*)

10:00 – 10:30 Break

10:30 – 11:00 Questions & Answers

11:00 – 12:00 Submitted papers and/or short invited talks

12:00 – 13:30 Lunch

#### Session 4. Towards Treatment I: endpoints for animal studies

Moderator: Matthew Frosch\*

Session to be organized around formulating proposed guidelines for animal studies aimed at identifying candidate CAA treatments for phase I-II human trials.

13:30 – 15:00 Plenaries

13:30 – 14:00 : Hemorrhages (*Jin-Moo Lee*)

14:00 – 14:30 : Amyloid and inflammation (*William Van Nostrand*)

14:30 – 15:00 : Physiologic markers (*Cenk Ayata*)

15:00 – 15:30 Break

15:30 – 17:00 Discussion (*discussion leader: Lee*)

19:00 Dinner for registrants and faculty  
Faculty Club Leiden University, Rapenburg 73, Leiden

## Friday, October 26

#### Session 5. Towards Treatment II: endpoints for human studies

Moderators: Eric Smith

Session to be organized around formulating proposed guidelines for human phase II studies aimed at identifying candidate CAA treatments for phase III clinical trials.

8:30 – 10:00 Presentation, discussion

8:30 – 9:00 : Physiologic endpoints (*Steven Greenberg*)

9:00 – 9:30 : Hemorrhagic endpoints (*Charlotte Cordonnier*)

9:30 – 10:00 : Cognitive endpoints (*Julie Schneider*)

10:00 – 10:30 Break

10:30 – 12:00 Discussion (*discussion leader: Greenberg*)

12:00 Adjourn